Nearly 30% of adults worldwide have fatty liver disease, and a Mayo Clinic team now says that single diagnosis covers five biologically distinct subtypes. Working with Virginia Tech, the group analyzed genetic and clinical data from more than 4,600 patients and reported the results in Nature Communications on September 2, according to Mayo Clinic’s announcement.

Doctors now call the condition metabolic dysfunction-associated steatotic liver disease, or MASLD (formerly NAFLD). Fat builds up in the liver, often without symptoms, and can progress to inflammation, scarring and irreversible damage. MASLD ranks among the leading causes of cirrhosis, liver cancer and liver transplants worldwide.

The subtypes carry different risks for heart disease, liver failure, cancer and transplant, but five labels in one paper don’t yet amount to five separate diseases.

Researchers Grouped Patients By Genes And Health Records

The team combined genetic sequencing with clinical data such as liver enzymes, body mass index, lipid levels and conditions like diabetes, depression and sleep apnea. Computational modeling then sorted patients who shared underlying biological signals into groups.

Researchers Grouped Patients By Genes And Health Records

The genetic side came from Mayo’s Research Data Atlas, a system that links genetic data to patient records. Its Tapestry Study has produced exome data from more than 100,000 participants. First author Tahmina Sultana Priya contributed while at Mayo and is now a Ph.D. student at Virginia Tech. The co-senior authors are Shulan Tian and Eric Klee.

“Once you separate these subtypes, you can start to match treatments to the biology that’s actually driving the disease,” Tian said.

Some Groups Follow Obesity And Diabetes While Others Follow Inherited Genes

According to the release, some subtypes are tied to obesity and diabetes. Others are driven by inherited genetic factors. The genetic subtypes carried a higher risk of progressing to advanced liver disease, including in patients without the usual metabolic risk factors.

Certain subtypes were also associated with depression, sleep apnea and migraine, a first according to the researchers, as SciTechDaily’s coverage notes. An association isn’t proof of cause, so the findings don’t show that fatty liver disease produces those conditions.

Earlier Studies Found Groups Too, With Different Counts And Labels

Two 2024 papers in Nature Medicine split patients differently, as a German Center for Diabetes Research press release describes. One found six clusters. Two of them stood out: a cardiometabolic cluster with a higher risk of heart disease and type 2 diabetes, plus a liver-specific cluster enriched for at-risk genetic variants, with rapid liver progression but relatively low heart risk. The other paper used genetic risk scores to separate a liver-specific type from a systemic one.

A 2025 study in the Journal of Translational Medicine, listed on UK Biobank’s publications page, clustered 125,197 UK Biobank participants with MASLD plus 995 health-exam patients from a Chinese hospital. It found five groups:

  • Metabolic-Dyslipidemia
  • Younger
  • Obesity
  • Inflammatory
  • Hepatotoxic

The Hepatotoxic group had a far higher risk of severe liver disease than the Metabolic-Dyslipidemia group (hazard ratio 13.9, 95% CI 10.7 to 18.1), while extrahepatic complications were highest in the Inflammatory group. These are a different five groups from Mayo’s. The varying counts suggest the number depends on the data and method used.

Coverage So Far Leaves Out The Subtype Names And Risk Numbers

Mayo’s release and the news coverage don’t name the five groups or give risk figures for each one. Funding isn’t described, and readers are pointed to the full study for that.

The researchers list two next steps: testing the approach in broader patient populations and checking how the subtypes respond to treatments, including GLP-1 receptor agonists. Our earlier piece on how a weight-loss hormone may protect the liver covers one treatment angle.

Your Next Checkup Won’t Look Different Yet

Sorting by subtype is a research tool for now. The coverage describes no test or treatment built on it.

Because the condition often causes no symptoms, people with obesity or diabetes can ask their doctor about checking their liver. Klee said the approach helps researchers “map complex disease with such precision that we can begin to anticipate its course,” in Medbound Times’ report.

For diet research on liver fat, see our earlier piece on tomatoes and less liver fat.

Leave a comment